NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by ...

From clinical developments to an upcoming FDA trial anticipated in 2025, Mainz Biomed NV MYNZ, the molecular genetics diagnostic company, is making headway in growing its business on its path to ...

Short interest in Mainz Biomed NV (NASDAQ:MYNZ) decreased during the last reporting period, falling from 1.70M to 1.52M. This put 8.25% of the company's publicly available shares short.

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...

In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with ...

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.